An interventional study of High power diode laser + SRT and Low diode diode laser + SRT in Periodontal Disease, sponsored by University of Science and Technology, Yemen. Active, not recruiting at 2 sites in Yemen. Open to participants aged 25 Years to 58 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by University of Science and Technology, Yemen · Not applicable, Interventional, and Treatment
The aim of this study is to evaluate the efficacy of diode laser in addition to periodontal treatment in periodontitis patients and to investigate their effects on gingival crevicular fluid (GCF) cytokine levels before and after treatment, among some Yemeni individuals in Sana'a city.
This study aims to compare the clinical and immunological effects of traditional mechanical debridement alone versus combined treatment with diode laser (high and low power). The clinical parameters include Plaque Index (PI), Gingival Index (GI), Periodontal Pocket Depth (PPD), and Clinical Attachment Loss (CAL). Immunological parameters include IL-1β, IL-6, IL-8, and TNF-α levels in GCF. Participants will be selected from the Yemeni population residing in Sana'a City. The study will include a control group receiving conventional therapy and two test groups receiving diode laser therapy with high and low intensity settings, respectively. Measurements will be recorded at baseline (T0), one month after treatment (T1), and three months post-treatment (T2).
The goal is to determine whether adjunctive diode laser therapy provides additional clinical and immunological benefits compared to conventional treatment alone.
1,231 studies on the registry are indexed under Periodontitis; 295 are open to participants now.
This study's planned enrollment of 21 is below the median of 44 across 846 interventional studies indexed under Periodontitis.
Browse Periodontitis studies →University of Science and Technology, Yemen is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Compared within Periodontitis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Periodontal Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients receive only subgingival curettage by curettes and ultrasonic scaler
Procedure: Curettage (SRT) only
Patients recieved high power diode laser (2W) after curettage to pocket disinfection and tissue healing
Procedure: High power diode laser + SRT · Procedure: Curettage (SRT) only
Low power laser(0. 5W) is applicated to patient after curettage
Procedure: Low diode diode laser + SRT · Procedure: Curettage (SRT) only
2W laser will be applied to periodontal pockets
A 0.5W low laser is applicated to periodontal pockets after mechanical debridement
Mechanical debridement for pocket
Plaque Index (PI)
Clinical evaluation of plaque index will be performed at three points before treatment (T0), 1 month (T1) anD 3 months (T2) after treatment to evaluate periodontal improvement
Time frame: Baseline,1 month, 3months after treatment
Gingival Index( GI)
Clinical evaluation of gingival index will be performed at three points before treatment (T0), 1 month (T1) anD 3 months (T2) after treatment to evaluate periodontal improvement
Time frame: Baseline,1 month, 3months after treatment
Periodontal Pocket Depth (PPD)
Clinical evaluation of periodontal pocket depth will be performed at three points before treatment (T0), 1 month (T1) anD 3 months (T2) after treatment to evaluate periodontal improvement
Time frame: Baseline,1 month, 3months after treatment
Clinical attachment level (CAL)
Clinical evaluation of clinical attachment level will be performed at three points before treatment (T0), 1 month (T1) anD 3 months (T2) after treatment to evaluate periodontal improvement
Time frame: Baseline,1 month, 3months after treatment
interleukin-6 (IL-6) levels in GCF
Levels of interleukin-6 (IL-6) in gingival crevicular fluid (GCF) will be measured at baseline, 1 month, and 3 months after treatment to assess immune response to o assess immune response to periodontal therapy.
Time frame: Baseline,1 month, 3months after treatment
interleukin-1B (IL-1B) levels in GCF
Levels of interleukin-1 beta (IL-1β) in gingival crevicular fluid (GCF) will be measured at baseline, 1 month, and 3 months after treatment to assess immune response to periodontal therapy
Time frame: Baseline,1 month, 3months after treatment
interleukin-8 (IL-8) levels in GCF
Levels of interleukin-8 (IL-8) in gingival crevicular fluid (GCF) will be measured at baseline, 1 month, and 3 months after treatment to assess immune response to o assess immune response to periodontal therapy.
Time frame: Baseline,1 month, 3months after treatment
tumor necrosis factor-alpha (TNF-α) levels in GCF
Levels of tumor necrosis factor-alpha (TNF-α) in gingival crevicular fluid (GCF) will be measured at baseline, 1 month, and 3 months after treatment to assess immune response to o assess immune response to periodontal therapy.
Time frame: Baseline,1 month, 3months after treatment
Plan to share: Yes — "De-identified individual participant data (IPD) including demographic information, treatment assignment, clinical outcomes, and cytokine levels will be shared. The data will be made available to qualified researchers for non-commercial academic use after publication of the primary results."
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Starting 6 months after publication, available for 5 years
Access criteria: Data will be shared upon reasonable request to the corresponding author via email
Data sharing details ↗ · www.ust.edu.ye
Started Jul 2025 (actual). Primary completion is estimated for Jun 2026, 11 months after the start.
Of 480 non-industry interventional studies with no phase under Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's planned 11 months is below that.
Counting every sponsor, half of 494 studies reached it within 16 months; a quarter within 8 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Science and Technology, Yemen